The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Increased Levels of Circulating Interleukin 6, Interleukin 8, C-Reactive Protein, and Risk of Lung Cancer
Open accessAbstract
BACKGROUND: Previous studies that were based primarily on small numbers of patients suggested that certain circulating proinflammatory cytokines may be associated with lung cancer; however, large independent studies are lacking. METHODS: Associations between serum interleukin 6 (IL-6) and interleukin 8 (IL-8) levels and lung cancer were analyzed among 270 case patients and 296 control subjects participating in the National Cancer Institute-Maryland (NCI-MD) case-control study. Results were validated in 532 case patients and 595 control subjects in a nested case-control study within the prospective Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Association with C-reactive protein (CRP), a systemic inflammation biomarker, was also analyzed. Associations between biomarkers and lung cancer were estimated using logistic regression models adjusted for smoking, stage, histology, age, and sex. The 10-year standardized absolute risks of lung cancer were estimated using a weighted Cox regression model. RESULTS: Serum IL-6 and IL-8 levels in the highest quartile were associated with lung cancer in the NCI-MD study (IL-6, odds ratio [OR] = 3.29, 95% confidence interval [CI] = 1.88 to 5.77; IL-8, OR = 2.06, 95% CI = 1.19 to 3.57) and with lung cancer risk in the PLCO study (IL-6, OR = 1.48, 95% CI = 1.04 to 2.10; IL-8, OR = 1.57, 95% CI = 1.10 to 2.24), compared with the lowest quartile. In the PLCO study, increased IL-6 levels were only associated with lung cancer diagnosed within 2 years of blood collection, whereas increased IL-8 levels were associated with lung cancer diagnosed more than 2 years after blood collection (OR = 1.57, 95% CI = 1.15 to 2.13). The 10-year standardized absolute risks of lung cancer in the PLCO study were highest among current smokers with high IL-8 and CRP levels (absolute risk = 8.01%, 95% CI = 5.77% to 11.05%). CONCLUSIONS: Although increased levels of both serum IL-6 and IL-8 are associated with lung cancer, only IL-8 levels are associated with lung cancer risk several years before diagnosis. Combination of IL-8 and CRP are more robust biomarkers than either marker alone in predicting subsequent lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Stewart, B. W., & Kleihues, P. (2003) · Cited by 2,386
Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
Kuilman, T., Michaloglou, C., Vredeveld, L. C. W., Douma, S., van Doorn, R., Desmet, C. J., Aarden, L. A., Mooi, W. J., & Peeper, D. S. (2008) · Cell · doi:10.1016/j.cell.2008.03.039 · Cited by 2,086 · cited 1×
“It was surprising that IL-8, but not IL-6, was associated with subsequent development of disease, especially because IL-6 and IL-8 are secreted by premalignant and senescent cells surrounding premalignant lesions (10,36,37), which would likely be present up to several years before lung cancer diagnosis.”
BackgroundA cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940 · cited 1×
“Under inflammatory stress, IL-6 and IL-8 participate in tumorigenesis by acting directly on lung epithelial cells via signaling through the nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NFKB1) pathway (30,32).”
BackgroundSurvival of Patients with Stage I Lung Cancer Detected on CT Screening
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa060476 · Cited by 1,706
Inflammation and cancer: An ancient link with novel potentials
Perwez Hussain, S., & Harris, C. C. (2007) · International Journal of Cancer · doi:10.1002/ijc.23173 · Cited by 1,097
Self-citationDesign of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
Prorok, P. C., Andriole, G. L., Bresalier, R. S., Buys, S. S., Chia, D., David Crawford, E., Fogel, R., Gelmann, E. P., Gilbert, F., Hasson, M. A., et al. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00098-2 · Cited by 1,037
Boyle, P., & Levin, B. L. (2009) · Cited by 770
Senescent cells as a source of inflammatory factors for tumor progression
Davalos, A. R., Coppe, J.-P., Campisi, J., & Desprez, P.-Y. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9220-9 · Cited by 636
Cited by
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
Gupta, S. C., Hevia, D., Patchva, S., Park, B., Koh, W., & Aggarwal, B. B. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4414 · Cited by 732
The CXCL8-CXCR1/2 pathways in cancer
Liu, Q., Li, A., Tian, Y., Wu, J. D., Liu, Y., Li, T., Chen, Y., Han, X., & Wu, K. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.08.002 · Cited by 662
The role of IL-6/JAK2/STAT3 signaling pathway in cancers
Huang, B., Lang, X., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023177 · Cited by 479
LIU, R.-Y., ZENG, Y., LEI, Z., WANG, L., YANG, H., LIU, Z., ZHAO, J., & ZHANG, H.-T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2310 · Cited by 308
Metadata
- Authors
- Pine, S. R., Mechanic, L. E., Enewold, L., Chaturvedi, A. K., Katki, H. A., Zheng, Y.-L., Bowman, E. D., Engels, E. A., Caporaso, N. E., & Harris, C. C.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-06-17
- Volume
- 103
- Issue
- 14
- Pages
- 1112-1122
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2096846592
- Cited by
- 333
- References
- 40
- FWCI
- 11.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased Levels of Circulating Interleukin 6, Interleukin 8, C-Reactive Protein, and Risk of Lung Cancer. https://app.cochat.ai/papers/10.1093/jnci/djr216
- The paper
- Pine, S. R., Mechanic, L. E., Enewold, L., Chaturvedi, A. K., Katki, H. A., Zheng, Y.-L., Bowman, E. D., Engels, E. A., Caporaso, N. E., & Harris, C. C. (2011). Increased Levels of Circulating Interleukin 6, Interleukin 8, C-Reactive Protein, and Risk of Lung Cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djr216
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.